|
Parameter
|
BAT SUVmax
|
BAT TMA
|
|---|
|
Mean ±SD
|
P value
|
Mean ± SD
|
P value
|
|---|
|
Age:
|
0.597a
|
|
< 50 years
|
13.7 ±10
|
0.683a
|
81.9 ± 47.8
|
|
≥ 50 years
|
10.5 ±10.6
|
63 ± 15.5
|
|
Disease stage:
|
0.883a
|
|
I & II
|
10 ±9.9
|
0.148a
|
81 .1 ± 54
|
|
III & IV
|
17 ±8.8
|
77.5 ± 34.6
|
|
Histology:
|
0.256b
|
|
IDC
|
13.2 ±10.4
|
0.978b
|
74.5 ± 33.8
|
|
ILC
|
13.5 ± 7.7
|
114.5 ± 13.8
|
|
Grade
|
0.521b
|
|
I
|
18.5±20.5
|
0.756b
|
92 ± 14
|
|
II
|
12.4± 8.5
|
87.8 ± 51.6
|
|
III
|
12.8 ± 10
|
59.6 ± 39.2
|
|
Molecular subtypes
|
=0.272b
|
|
Luminal A
|
17±13.4
|
0.272b
|
72.4 ± 21.2
|
|
Luminal B
|
10 ±5.7
|
92.5 ± 55.5
|
|
Basal-like
|
9.3 ±8.7
|
43.3 ± 32.5
|
|
HER2+ve
|
28 ± 0
|
133 ± 0
|
|
ER receptor status
|
0.831a
|
|
Positive
|
13.5 ± 10
|
0.936a
|
81.3 ± 45
|
|
Negative
|
13 ±10
|
75.8 ± 50.4
|
|
PR receptor status
|
0.951a
|
|
Positive
|
14.5±10
|
0.554a
|
79 ± 47
|
|
Negative
|
11.3 ± 10
|
80 ± 46.5
|
|
Her2-receptor status
|
0.019a
|
|
Positive
|
11.6 ± 10
|
0.657a
|
117.2± 56.4
|
|
Negative
|
14 ± 10.4
|
62.5 ± 27.5
|
|
Ki-level
|
0.552b
|
|
<14
|
33 ± 0
|
0.112b
|
102 ± 0
|
|
≥14
|
11.4 ± 6
|
89.3 ± 52.2
|
|
Not assessed
|
12.7± 11
|
65.3 ± 38.4
|
|
N-stage:
|
0.626a
|
|
N0
|
13 ± 12.9
|
0.936a
|
71 ± 25.1
|
|
N1-3 (mean)
|
13.5 ±12
|
83.5 ± 52.5
|
|
M-stage
|
0.868a
|
|
M0
|
24.6 ± 4.9
|
0.021a
|
78.6 ± 47.3
|
|
M1
|
10.6 ± 8.8
|
83.7 ± 43.3
|
- aIndependent sample T test, bOne-way ANOVA
- SUVmax maximum standardized uptake value, TMA total metabolic activity
